Key result
The emPHasis-10 score correlates with clinical parameters in PAH, yielding a ~6-point minimally important difference.
Why the study?
The performance of the emPHasis-10 score had only been evaluated against limited patient characteristics in the United Kingdom, leaving an unmet need to explore its performance among US patients with pulmonary arterial hypertension.
Observational (n=565)
Yes
Effect estimate: MID -6.0 points
The emPHasis-10 score is a valid measure of health-related quality of life in US patients with PAH, correlating with clinical severity markers and having a minimally important difference of -6.0 points.
No takes yet. Share an insight, caveat, or question.
Supports emPHasis-10 for PAH monitoring; extends validation data but leaves open prospective outcome trials.
Borgese et al. (2020) conducted an observational in pulmonary arterial hypertension (n=565). emPHasis-10 (e10) score was evaluated on minimally important difference (MID) estimate for the e10 score (MID -6.0 points). The emPHasis-10 score correlated with clinical parameters including 6-minute walk distance and BNP/NT-proBNP in PAH patients, with a derived minimally important difference estimate of -6.0 points.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: